Select Medical (NYSE: SEM) shareholders approve $3.9bn buyout as founder-led consortium nears takeover

Select Medical Holdings Corporation (NYSE: SEM) shareholders have approved the company’s proposed acquisition by a consortium led by co-founder Robert A. Ortenzio, senior executive Martin F. Jackson and Welsh, Carson, Anderson & Stowe. Investors will receive $16.50 in cash for each eligible share under a transaction valuing the healthcare provider at approximately $3.9 billion, including debt. More than 79.88% of all outstanding shares supported the merger, while over 76.64% of shares held by investors unaffiliated with the consortium voted in favour. The approval removes one of the most important conditions facing the insider-led take-private transaction, although healthcare regulatory approvals and other closing requirements remain. Select Medical expects the acquisition to close in mid-2026, after which SEM shares will be delisted from the New York Stock Exchange.

Why does shareholder approval materially reduce risk for Select Medical’s $3.9 billion take-private deal?

Approximately 82.54% of Select Medical’s outstanding shares participated in the special meeting, providing the transaction with a strong turnout as well as approval from both the overall shareholder base and the required majority of unaffiliated investors. The separate minority vote was particularly important because the buying group includes executives and directors who already possess substantial influence over the company. Without support from unaffiliated shareholders, the consortium could not have relied solely on insider holdings to push the transaction through.

The vote reduces the probability that shareholder opposition will block the acquisition. It also gives lenders and regulatory authorities greater certainty that the ownership transition has sufficient investor support. The transaction still requires completion of remaining conditions, but the principal public-company governance hurdle has now been cleared.

The result suggests that most investors preferred the certainty of receiving $16.50 in cash rather than retaining exposure to Select Medical’s operating risks as an independent listed company. These risks include labour shortages, reimbursement pressure, rising service costs and uneven profitability across the company’s hospital and outpatient rehabilitation businesses.

However, a successful vote does not establish that every investor believes the price represents the maximum possible value. Shareholders often approve cash acquisitions because the alternative is uncertain, particularly when the stock has already moved close to the offer price and no superior bidder has emerged.

The special committee approached ten potential strategic and financial buyers during the sale process, but the consortium’s proposal ultimately became the transaction presented to shareholders. The absence of a higher competing bid strengthened the practical case for approval, even though it did not eliminate debate over whether a longer recovery in operating performance could have produced greater value.

What does the $16.50 cash offer reveal about valuation and minority shareholder trade-offs?

The $16.50 offer represents an approximately 18% premium to Select Medical’s unaffected share price of $14.01 on November 24, 2025, before the founder-led proposal became public. It also represents an approximately 25% premium to the 90-day volume-weighted average price for the period ending on that date. The transaction values the company at approximately $3.9 billion on an enterprise-value basis.

Those premiums provide investors with immediate liquidity and remove exposure to future earnings volatility. Select Medical operates businesses that depend heavily on government and commercial reimbursement, qualified clinical labour and effective hospital utilisation. A cash exit transfers those operating risks from public shareholders to the consortium.

The price nevertheless sits toward the lower end of some valuation ranges examined during the fairness process. Goldman Sachs’ illustrative discounted cash flow analysis produced a range of approximately $14.04 to $25.72 per share, while an illustrative premium analysis generated a range of $15.69 to $24.80. These ranges do not prove that Select Medical was worth the highest figure, but they show that the $16.50 consideration was not positioned near the upper boundary of every valuation method considered.

This creates the central trade-off for minority investors. They receive a premium and avoid future execution risk, but they surrender participation in any improvement generated after the business becomes private. If the consortium expands the rehabilitation hospital network, restores critical illness recovery margins and later sells or relists the business at a higher valuation, current public investors will not share in that upside.

The cash structure also means the transaction will generally create a taxable event for applicable United States shareholders. This reduces the effective premium for some investors, although individual tax consequences depend on purchase price, holding period and personal circumstances.

In our view, the offer represents a credible certainty premium rather than an obviously generous strategic takeover valuation. Shareholders are being paid to exit a business facing meaningful reimbursement and labour risks, while the buyers are retaining the opportunity to capture the benefits of a multiyear operational improvement.

Why are governance and insider conflicts central to the Select Medical take-private transaction?

Robert A. Ortenzio is Select Medical’s executive chairman, co-founder and a director, while Martin F. Jackson serves as senior executive vice president of strategic finance and operations. Their involvement gives the consortium detailed knowledge of the company’s facilities, payer relationships, expansion pipeline and operating challenges that outside bidders would find difficult to replicate.

That knowledge can improve execution after closing, but it also creates an inherent conflict. The same executives who understand Select Medical’s long-term potential are participating in the group buying the company from public shareholders. They may benefit from future improvements that existing investors are being asked to exchange for a fixed cash payment.

The transaction used a special committee of independent directors to evaluate the proposal, negotiate terms and assess alternatives. The disinterested board members accepted the committee’s recommendation and determined that the merger was fair to unaffiliated shareholders. Ortenzio did not participate in the special committee’s deliberations.

The unaffiliated shareholder vote provided another important protection. Ortenzio-controlled holdings represented approximately 11% of voting power when the deal was signed, while Jackson controlled approximately 1%. Their shares are being rolled into the buyer rather than cashed out on the same basis as ordinary public investors.

Rollover equity aligns the executives with the future performance of the private company, but it also means they receive an investment opportunity unavailable to most shareholders. Public investors must sell for $16.50, while participating insiders can maintain exposure to future appreciation.

The strong minority vote indicates that most unaffiliated investors accepted the process and price despite this difference. Yet the governance question will remain relevant when assessing the transaction historically. The consortium is buying a business it already knows intimately, using a structure that allows insiders to remain invested while the broader shareholder base exits.

How could private ownership change Select Medical’s hospital expansion and capital allocation?

Select Medical operates 103 critical illness recovery hospitals, 41 rehabilitation hospitals and 1,912 outpatient rehabilitation clinics across the United States and the District of Columbia. This creates a diversified post-acute care platform, but each operating segment currently presents a different margin and growth profile.

The rehabilitation hospital segment has been the strongest growth engine. First-quarter revenue increased 14.5% to $351.9 million, while adjusted EBITDA rose 15.1% to $81.1 million. The segment operated at a 23% adjusted EBITDA margin, considerably above the margins reported by Select Medical’s critical illness recovery and outpatient rehabilitation businesses.

Private ownership could allow the consortium to direct more capital toward rehabilitation hospitals without explaining every quarter of elevated construction spending to public investors. These facilities can be developed through partnerships with health systems, providing Select Medical with referral relationships and local clinical credibility while sharing some project risk.

The critical illness recovery segment presents a more difficult operational challenge. First-quarter revenue increased only 0.3% to $638.8 million, while adjusted EBITDA fell 15.3% to $73.4 million. Its margin contracted from 13.6% to 11.5%, reflecting weaker patient days, lower occupancy and operating-cost pressure.

Outpatient rehabilitation revenue rose 4.5% to $321.3 million, but adjusted EBITDA declined 9.4% to approximately $22 million. The margin fell from 7.9% to 6.8%, even as patient visits increased. This suggests that volume growth alone is not offsetting wage, administrative and facility costs.

The private owners could respond by accelerating clinic consolidation, renegotiating leases, investing in scheduling technology or exiting weaker markets. Such decisions may be easier outside public markets, particularly when short-term restructuring costs are required before margins improve.

The consortium may also pursue acquisitions or new hospital joint ventures without the same level of quarterly scrutiny. However, private ownership does not magically improve reimbursement or recruit scarce therapists. The operational work remains stubbornly real, even when the earnings call disappears.

Can Select Medical carry additional transaction debt while operating margins remain under pressure?

The acquisition financing includes up to $880 million of equity committed by Welsh, Carson, Anderson & Stowe, executive rollover shares and committed debt financing. The initial debt commitment included up to $1 billion of senior secured bridge loans, with JPMorgan Chase Bank and Wells Fargo among the financing providers. The merger agreement does not include a buyer financing condition, reducing the risk that the consortium can abandon the acquisition merely because lending markets become less convenient.

Select Medical already reported approximately $1.86 billion of current and long-term debt at March 31, 2026, excluding operating lease liabilities. Cash and cash equivalents stood at only $25.7 million, while net cash from operating activities reached $37.9 million during the quarter.

The transaction’s $3.9 billion enterprise value incorporates this existing indebtedness. The final post-closing capital structure will depend on how bridge financing is refinanced, the amount of insider equity rolled over and whether existing obligations remain outstanding or are replaced.

Debt can increase private equity returns when earnings grow, but it also reduces flexibility when operating performance weakens. Select Medical’s first-quarter revenue rose 5% to $1.42 billion, yet adjusted EBITDA declined from $151.4 million to $141.6 million. Net income attributable to Select Medical shareholders fell 22.4% to approximately $44 million.

Management maintained its 2026 outlook for revenue of $5.6 billion to $5.8 billion and adjusted EBITDA of $520 million to $540 million. At the midpoint, the $3.9 billion enterprise value represents roughly 7.4 times expected adjusted EBITDA before considering future growth, integration costs or transaction-related financing changes.

That multiple is not excessive for a large healthcare services platform, but the equity case depends on improving margins rather than relying only on revenue growth. Labour costs, reimbursement changes and clinician availability can quickly absorb additional patient volume.

The consortium’s healthcare experience may help it prioritise capital and operational initiatives. Welsh, Carson, Anderson & Stowe has specialised in healthcare and technology investing, and its $5 billion WCAS XIV fund provides substantial equity capacity. Nevertheless, financial sponsorship cannot remove the regulatory and labour constraints affecting post-acute care providers.

What does SEM’s deal-price trading pattern reveal about investor expectations before closing?

Select Medical shares ended June 26 at approximately $16.50, matching the cash merger consideration. The stock has remained tightly anchored around the offer price, declining roughly 0.2% over both the latest five-day period and the month since May 26. Its 52-week range stands at approximately $11.65 to $16.99.

Trading directly at the offer price indicates that investors see a high probability of completion and limited opportunity for a competing bidder to emerge. When meaningful closing risk remains, a takeover target typically trades at a wider discount to the agreed consideration.

The narrow spread also means there is little conventional upside left for new investors purchasing SEM shares. A buyer at $16.50 would receive the same amount when the merger closes, excluding any effect from settlement timing or other distributions. The position therefore offers almost no return unless another bidder appears or the terms change.

The downside would be more substantial if the acquisition failed. Before the proposal became public, Select Medical traded at $14.01, while its 52-week low was $11.65. Operating performance has changed since then, but these figures illustrate the potential price risk if the deal were terminated.

The stock market is therefore treating SEM less like an operating healthcare equity and more like a short-duration merger security. Revenue growth, hospital openings and reimbursement developments matter mainly to the extent that they influence closing conditions or the buyer’s willingness to complete the transaction.

What could still delay the Select Medical acquisition after the shareholder vote?

Select Medical must obtain the remaining healthcare regulatory approvals and satisfy customary conditions before the merger can close. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on April 27, reducing federal antitrust uncertainty, but healthcare licences and change-of-control approvals can involve multiple states and facility types.

The transaction must also avoid a material adverse change and satisfy financing documentation requirements. Although the deal has no financing condition, the equity and debt commitments contain customary conditions tied to closing, financial information and representations made by the parties.

Another unusual condition involves the earlier spin-off of Concentra Group Holdings Parent, Inc. Select Medical expects to receive a tax opinion confirming that the merger will not cause the Concentra distribution to lose its tax-free treatment. Failure to secure that opinion could complicate or delay closing.

The shareholder approval substantially improves transaction certainty, but it does not eliminate administrative execution. Select Medical operates thousands of facilities across dozens of states, meaning ownership changes require considerably more paperwork than changing the name above one hospital entrance.

The most likely outcome remains completion near the agreed $16.50 price. Once the acquisition closes, attention will shift from whether the transaction happens to whether the consortium can create enough operational and strategic value to justify the purchase, financing costs and insider rollover structure.

What are the key takeaways from Select Medical’s approved $3.9 billion take-private acquisition?

• Select Medical shareholders have approved the $16.50-per-share acquisition by Robert A. Ortenzio, Martin F. Jackson and Welsh, Carson, Anderson & Stowe.
• More than 76.64% of unaffiliated shares supported the merger, satisfying an important minority shareholder approval condition.
• The transaction values Select Medical at approximately $3.9 billion, including debt, and carries an 18% premium to the unaffected November 2025 price.
• The insider-led structure creates governance tension because participating executives can retain exposure through rollover equity while public investors must cash out.
• SEM shares are trading near the $16.50 consideration, suggesting investors expect the transaction to close with limited chance of a higher offer.
• Select Medical’s rehabilitation hospitals are growing strongly, while critical illness recovery and outpatient rehabilitation margins remain under pressure.
• The company reported first-quarter revenue growth of 5%, but adjusted EBITDA and shareholder earnings declined.
• Existing debt, transaction financing and low cash reserves make margin improvement important to the consortium’s future investment returns.
• Remaining risks include healthcare regulatory approvals, financing documentation and a tax opinion related to the earlier Concentra separation.
• Public shareholders receive price certainty but surrender any upside from a successful private-market restructuring and eventual resale or relisting.